JP3837711B2 - リソソーム蓄積症の早期検出方法 - Google Patents
リソソーム蓄積症の早期検出方法 Download PDFInfo
- Publication number
- JP3837711B2 JP3837711B2 JP54126497A JP54126497A JP3837711B2 JP 3837711 B2 JP3837711 B2 JP 3837711B2 JP 54126497 A JP54126497 A JP 54126497A JP 54126497 A JP54126497 A JP 54126497A JP 3837711 B2 JP3837711 B2 JP 3837711B2
- Authority
- JP
- Japan
- Prior art keywords
- lamp
- molecule
- lsd
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title claims abstract description 112
- 238000001514 detection method Methods 0.000 title abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 claims description 53
- 108090000790 Enzymes Proteins 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims description 21
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 claims description 17
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 claims description 17
- 210000003712 lysosome Anatomy 0.000 claims description 13
- 230000001868 lysosomic effect Effects 0.000 claims description 13
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 10
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 7
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 7
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 7
- 206010072927 Mucolipidosis type I Diseases 0.000 claims description 6
- 208000013608 Salla disease Diseases 0.000 claims description 6
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- -1 lanthanoid metals Chemical class 0.000 claims description 5
- 208000015872 Gaucher disease Diseases 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000035051 Malignant migrating focal seizures of infancy Diseases 0.000 claims 1
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 101150048357 Lamp1 gene Proteins 0.000 abstract description 21
- 102000019199 alpha-Mannosidase Human genes 0.000 abstract description 14
- 108010012864 alpha-Mannosidase Proteins 0.000 abstract description 14
- 102000013563 Acid Phosphatase Human genes 0.000 abstract description 6
- 108010051457 Acid Phosphatase Proteins 0.000 abstract description 6
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 abstract description 5
- 101150117895 LAMP2 gene Proteins 0.000 abstract description 5
- 239000000032 diagnostic agent Substances 0.000 abstract description 3
- 229940039227 diagnostic agent Drugs 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 112
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 77
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 77
- 229940088598 enzyme Drugs 0.000 description 51
- 239000002609 medium Substances 0.000 description 43
- 229930006000 Sucrose Natural products 0.000 description 34
- 239000005720 sucrose Substances 0.000 description 34
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 33
- 239000003550 marker Substances 0.000 description 33
- 239000000523 sample Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 238000003556 assay Methods 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 210000002950 fibroblast Anatomy 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 230000002132 lysosomal effect Effects 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 238000003018 immunoassay Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 238000009825 accumulation Methods 0.000 description 19
- 238000012937 correction Methods 0.000 description 19
- 238000010166 immunofluorescence Methods 0.000 description 18
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 16
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000001493 electron microscopy Methods 0.000 description 13
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000001573 invertase Substances 0.000 description 12
- 235000011073 invertase Nutrition 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000003934 vacuole Anatomy 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 9
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 210000001626 skin fibroblast Anatomy 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000002820 assay format Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000000635 electron micrograph Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002641 enzyme replacement therapy Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 108010045758 lysosomal proteins Proteins 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 238000002731 protein assay Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 3
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 3
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 102000030902 Galactosyltransferase Human genes 0.000 description 3
- 108060003306 Galactosyltransferase Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 3
- 208000014060 Niemann-Pick disease Diseases 0.000 description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001044 red dye Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 2
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 238000013216 cat model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 2
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008723 osmotic stress Effects 0.000 description 2
- 210000005152 placental membrane Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011537 solubilization buffer Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical group C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- WVVLURYIQCXPIV-UHFFFAOYSA-N 4,4,4-trifluoro-1-naphthalen-2-ylbutane-1,3-dione Chemical compound C1=CC=CC2=CC(C(=O)CC(=O)C(F)(F)F)=CC=C21 WVVLURYIQCXPIV-UHFFFAOYSA-N 0.000 description 1
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000017462 Galactosialidosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 206010072928 Mucolipidosis type II Diseases 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 201000006486 beta-mannosidosis Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 description 1
- 208000027333 mucopolysaccharidosis type IIID Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ZMBHCYHQLYEYDV-UHFFFAOYSA-N trioctylphosphine oxide Chemical compound CCCCCCCCP(=O)(CCCCCCCC)CCCCCCCC ZMBHCYHQLYEYDV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN9917A AUPN991796A0 (en) | 1996-05-17 | 1996-05-17 | Early detection of lysosomal storage disorders |
| AU9917 | 1996-05-17 | ||
| PCT/AU1997/000304 WO1997044668A1 (en) | 1996-05-17 | 1997-05-16 | Early detection of lysosomal storage disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005283143A Division JP4260152B2 (ja) | 1996-05-17 | 2005-09-28 | リソソーム蓄積症の早期検出方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001519894A JP2001519894A (ja) | 2001-10-23 |
| JP3837711B2 true JP3837711B2 (ja) | 2006-10-25 |
Family
ID=3794228
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54126497A Expired - Fee Related JP3837711B2 (ja) | 1996-05-17 | 1997-05-16 | リソソーム蓄積症の早期検出方法 |
| JP2005283143A Expired - Fee Related JP4260152B2 (ja) | 1996-05-17 | 2005-09-28 | リソソーム蓄積症の早期検出方法 |
| JP2008211239A Withdrawn JP2008289501A (ja) | 1996-05-17 | 2008-08-19 | リソソーム蓄積症の早期検出方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005283143A Expired - Fee Related JP4260152B2 (ja) | 1996-05-17 | 2005-09-28 | リソソーム蓄積症の早期検出方法 |
| JP2008211239A Withdrawn JP2008289501A (ja) | 1996-05-17 | 2008-08-19 | リソソーム蓄積症の早期検出方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6759189B1 (https=) |
| EP (1) | EP1021725B1 (https=) |
| JP (3) | JP3837711B2 (https=) |
| AT (1) | ATE426169T1 (https=) |
| AU (1) | AUPN991796A0 (https=) |
| CA (2) | CA2731490A1 (https=) |
| DE (1) | DE69739317D1 (https=) |
| IL (1) | IL127033A (https=) |
| NZ (1) | NZ332641A (https=) |
| WO (1) | WO1997044668A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1181550A4 (en) * | 1999-04-30 | 2005-03-02 | Nathan S Kline Inst For Psychi | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US7090987B1 (en) | 1999-04-30 | 2006-08-15 | Nixon Ralph A | Methods for the identification of compounds for the treatment of neuronal atrophy-associated dementia |
| ATE550664T1 (de) | 2003-03-31 | 2012-04-15 | Womens & Childrens Hospital | Multiplex-screening auf lysosomale speicherkrankheiten (lsds) |
| US7615224B2 (en) | 2004-12-02 | 2009-11-10 | Women's And Children's Hospital | Multiplex-bead complex for determination of lysosomal storage disorders |
| ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
| WO2007136782A2 (en) * | 2006-05-19 | 2007-11-29 | Historx, Inc. | Kits and methods for evaluating misfolded proteins |
| WO2008070892A1 (en) * | 2006-12-13 | 2008-06-19 | Tgr Biosciences Pty Ltd | Promoting production of extracellular matrix by fibroblast cells and/or promoting migration of fibroblast cells |
| AU2009223092A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc | Treatment of Pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| US8497122B2 (en) * | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| GB201114909D0 (en) * | 2011-08-30 | 2011-10-12 | San Raffaele Centro Fond | Biomarkers for lysosomal storage disorders |
| US8293487B1 (en) * | 2012-01-06 | 2012-10-23 | Jiandi Zhang | Zestern, a simple, fast, specific and quantifiable improvement of immunodetection process |
| WO2014153083A1 (en) | 2013-03-14 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for predicting age of onset of a lysosomal storage disease or a disease associated with a lysosomal defect |
| US12020820B1 (en) | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| US11335461B1 (en) | 2017-03-06 | 2022-05-17 | Cerner Innovation, Inc. | Predicting glycogen storage diseases (Pompe disease) and decision support |
| US11923048B1 (en) | 2017-10-03 | 2024-03-05 | Cerner Innovation, Inc. | Determining mucopolysaccharidoses and decision support tool |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859581A (en) * | 1986-03-10 | 1989-08-22 | Board Of Regents, The University Of Texas System | Endoglycosidase assay |
| AU2990692A (en) | 1991-12-06 | 1993-06-10 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic method for pompe's disease |
| WO1994010340A1 (en) * | 1992-10-30 | 1994-05-11 | Mt. Sinai Hospital Corporation | Method for measuring glycosyltransferase activity |
-
1996
- 1996-05-17 AU AUPN9917A patent/AUPN991796A0/en not_active Abandoned
-
1997
- 1997-05-16 JP JP54126497A patent/JP3837711B2/ja not_active Expired - Fee Related
- 1997-05-16 WO PCT/AU1997/000304 patent/WO1997044668A1/en not_active Ceased
- 1997-05-16 US US09/180,657 patent/US6759189B1/en not_active Expired - Fee Related
- 1997-05-16 NZ NZ332641A patent/NZ332641A/xx not_active IP Right Cessation
- 1997-05-16 CA CA2731490A patent/CA2731490A1/en not_active Abandoned
- 1997-05-16 CA CA2253875A patent/CA2253875C/en not_active Expired - Fee Related
- 1997-05-16 IL IL12703397A patent/IL127033A/xx not_active IP Right Cessation
- 1997-05-16 DE DE69739317T patent/DE69739317D1/de not_active Expired - Lifetime
- 1997-05-16 AT AT97920460T patent/ATE426169T1/de not_active IP Right Cessation
- 1997-05-16 EP EP97920460A patent/EP1021725B1/en not_active Expired - Lifetime
-
2004
- 2004-01-13 US US10/756,011 patent/US20040191847A1/en not_active Abandoned
-
2005
- 2005-09-28 JP JP2005283143A patent/JP4260152B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-19 JP JP2008211239A patent/JP2008289501A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ332641A (en) | 2000-05-26 |
| US20040191847A1 (en) | 2004-09-30 |
| DE69739317D1 (de) | 2009-04-30 |
| ATE426169T1 (de) | 2009-04-15 |
| EP1021725B1 (en) | 2009-03-18 |
| CA2731490A1 (en) | 1997-11-27 |
| IL127033A0 (en) | 1999-09-22 |
| AUPN991796A0 (en) | 1996-06-13 |
| JP4260152B2 (ja) | 2009-04-30 |
| WO1997044668A1 (en) | 1997-11-27 |
| JP2008289501A (ja) | 2008-12-04 |
| CA2253875A1 (en) | 1997-11-27 |
| JP2006061161A (ja) | 2006-03-09 |
| EP1021725A1 (en) | 2000-07-26 |
| IL127033A (en) | 2000-12-06 |
| JP2001519894A (ja) | 2001-10-23 |
| US6759189B1 (en) | 2004-07-06 |
| CA2253875C (en) | 2011-02-22 |
| EP1021725A4 (en) | 2002-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3837711B2 (ja) | リソソーム蓄積症の早期検出方法 | |
| US9448232B2 (en) | Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis | |
| CN100401068C (zh) | 肝细胞癌的诊断 | |
| US9250248B2 (en) | Early detection of diabetes | |
| WO2013132347A2 (en) | Improved elisa immunoassay for calprotectin | |
| JP2009529885A (ja) | リソソーム酵素に対する抗体の検出のためのアッセイ | |
| US20080171344A1 (en) | Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase | |
| ES2281364T3 (es) | Rechazo de trasplante de organos y a las patologias asociadas. | |
| JP2010139511A (ja) | サポシンおよび他のマーカーを用いるリソソーム貯蔵障害の診断 | |
| US20040248216A1 (en) | Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor | |
| CA2417465C (en) | Organ transplant rejection and associated conditions | |
| AU714818B2 (en) | Early detection of lysosomal storage disorders | |
| JP3015121B2 (ja) | 非Ａ１ｃ糖化ヘモグロビンに対するモノクローナル抗体 | |
| JP2878317B2 (ja) | ラミニン測定試薬 | |
| JP4993065B2 (ja) | 肝細胞癌の診断方法 | |
| CN109613262A (zh) | 一种额颞叶痴呆试剂盒 | |
| JP2866151B2 (ja) | カルパスタチン異常症の検出方法及びキット | |
| CN119395305A (zh) | 血清sirt3作为肺动脉高压生物标志物的应用 | |
| JPH08143599A (ja) | ヒト由来のチトクロムｐ４５０１ａ１を認識する抗体 | |
| JP5182684B2 (ja) | カルボキシエチルアルギニンに対する抗体 | |
| JPH0827199A (ja) | ヒト由来のチトクロムｐ４５０２ｄ６を認識する抗体 | |
| JPH08143600A (ja) | ヒト由来のチトクロムｐ４５０１ａ２を認識する抗体 | |
| JPH10221344A (ja) | レンチルレクチン結合性コリンエステラーゼの測定法 | |
| JP2008503718A (ja) | 良性前立腺過形成のマーカーとしてのｊｍ−２７ | |
| JPS6347664A (ja) | 癌抗原測定法及びそのためのキツト |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050329 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050623 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050928 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060315 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060406 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060629 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060721 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090811 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100811 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110811 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |